Agios Pharmaceuticals Shares Plunge Following Novo Nordisk Clinical Success

Shares of Agios Pharmaceuticals (AGIO) experienced a sharp decline this week, falling 26.8% as investors reacted to intensifying competitive pressure in the sickle cell disease (SCD) treatment market. The sell-off follows the release of top-line Phase 3 trial results from Novo Nordisk (NVO) regarding its drug candidate, etavopivat. Both companies are developing oral pyruvate kinase (PK) activators designed to affect red blood cell metabolism in SCD patients. However, Novo Nordisk's etavopivat demonstrated a clinical advantage over Agios' mitapivat. Novo reported that etavopivat successfully met both of its primary endpoints, improving hemoglobin response and reducing vaso-occlusive crises (VOCs). In contrast, while Agios' mitapivat achieved its primary endpoint for hemoglobin response, it failed to meet the primary endpoint regarding the annualized rate of sickle cell pain crises (SCPCs) when compared to a placebo. This disparity in trial outcomes has cast doubt on the market potential and the regulatory pathway for the Agios candidate. Agios is currently working with the FDA to achieve alignment on a trial necessary for submission under an accelerated approval process. Despite the current setback, the company maintains a potential catalyst for 2026, with results for another PK activator, tebapivat, expected in the second half of the year.